THE LATEST FROM RAKOVINA
Discovery in motion.
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
DOWNLOAD Vancouver, British Columbia, November 28, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news...
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
DOWNLOAD Data highlights progress in Rakovina’s AI-derived PARP-1 inhibitor program Vancouver, British Columbia, November 24, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies...
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
DOWNLOAD Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in PTEN-deficient tumor models Vancouver, British Columbia, November 24, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”)...
Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
DOWNLOAD Vancouver, British Columbia, November 18, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and...
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
DOWNLOAD Vancouver, British Columbia, November 10, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the "Company") (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new data will...
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
PDF Version Vancouver, British Columbia, October 27, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR-NCI-EORTC International Conference on Molecular...
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
DOWNLOAD Vancouver, British Columbia, October 16, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new preclinical...
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
DOWNLOAD Vancouver, British Columbia, September 4, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive...
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
DOWNLOAD Vancouver, British Columbia, September 4, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive...
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, August 28, 2025 – Rakovina Therapeutics Inc. (“Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...
Rakovina Therapeutics Announces Stock Option Grants
DOWNLOAD VANCOUVER, BC, July 29, 2025 - Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the "Company" or "Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that...
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
DOWNLOAD Vancouver, British Columbia, August 26, 2025 – Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through Al-powered drug discovery, today announced that Chief Scientific...
